NDAORALTABLET, DELAYED RELEASE
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
THIOLA EC (tiopronin) by Mission Pharmacal is cystine disulfide reduction [moa]. Approved for reducing and complexing thiol [epc]. First approved in 2019.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THIOLA EC (tiopronin) is an oral delayed-release tablet approved in June 2019 for the treatment of cystinuria by reducing urinary cystine excretion. It functions as a reducing and complexing thiol agent that works through cystine disulfide reduction, forming soluble complexes that decrease stone formation risk. THIOLA EC represents the enteric-coated formulation of tiopronin, designed to improve gastrointestinal tolerability compared to immediate-release formulations in this rare genetic disorder treatment landscape.
$0.0BPart D
12.5 years to LOEMechanism of Action
Cystine Disulfide Reduction
Pharmacologic Class:
Reducing and Complexing Thiol
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product supports specialized roles including rare disease brand managers, medical science liaisons with nephrology/urology focus, and field teams servicing a concentrated patient base of cystinuria patients. Success requires deep knowledge of rare genetic disorders, payer relationships in specialty pharmacy, and small patient population engagement strategies. Currently zero open positions are linked to this product, reflecting the stable, mature commercial team structure typical of rare disease assets.
Company
Worked on THIOLA EC at Mission Pharmacal? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.